Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction

Molecular Carcinogenesis

Volumn 52, Issue SUPPL1, 2013, Pages 139-147

  Hassan, Manal M ^a   Kaseb, Ahmed ^a   Etzel, Carol J ^a   El Serag, Hashem ^b   Spitz, Margaret R ^b   Chang, Ping ^a   Hale, Katherine S ^a   Liu, Mei ^a   Rashid, Asif ^a   Shama, Mohamed ^a   Abbruzzese, James L ^a   Loyer, Evelyne M ^a   Kaur, Harmeet ^a   Hassabo, Hesham M ^a   Vauthey, Jean Nicolas ^a   Wray, Curtis J ^c   Hassan, Basmah S ^a   Patt, Yehuda Z ^d   Hawk, Ernest ^a   Soliman, Khalid M ^a   Li, Donghui ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Case control; Genetic susceptibility; Molecular epidemiology; Single nucleotide polymorphism

Indexed keywords

PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PHOSPHOLIPASE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

CASE-CONTROL; GENETIC SUSCEPTIBILITY; MOLECULAR EPIDEMIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LIPASE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84886308722     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22057     Document Type: Article

References (38)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491.
2. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40:1387-1395.
3. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29:198-206.
4. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: Hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004; 141:946-956.
5. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41:845-850.
6. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science 2011; 332:1519-1523.
7. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13:511-531.
8. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010; 51:1820-1832.
9. Kishino T, Ohnishi H, Ohtsuka K, et al. Low concentrations of serum n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease patients with liver injury. Clin Chem Lab Med 2011; 49:159-162.
10. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114:147-152.
11. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
12. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83:520-528.
13. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1209-1217.
14. Valenti L, Rumi M, Galmozzi E, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011; 53:791-799.
15. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52:894-903.
16. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50:2111-2116.
17. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36:1206-1213.
18. Hassan MM, Spitz MR, Thomas MB, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. Int J Cancer 2008; 123:1883-1891.
19. Hassan MM, Spitz MR, Thomas MB, et al. The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States. J Hepatol 2009; 50:334-341.
20. Hassan MM, Kaseb A, Li D, et al. Association between hypothyroidism and hepatocellular carcinoma: A case-control study in the United States. Hepatology 2009; 49:1563-1570.
21. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116:1938-1946.
22. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52:1056-1060.
23. Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 2010; 11:172.
24. Falleti E, Fabris C, Cmet S, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: Relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011; 31:1137-1143.
25. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. J Hepatol 2006; 44:158-166.
26. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421-427.
27. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 2005; 103:749-755.
28. Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578-586.
29. Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: Patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol 2010; 21:247-252.
30. Lake AC, Sun Y, Li JL, et al. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J Lipid Res 2005; 46:2477-2487.
31. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285:6706-6715.
32. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290:G852-G858.
33. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346:987-990.
34. Xu L, Han C, Lim K, Wu T. Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res 2006; 66:11859-11868.
35. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005; 42:987-1000.
36. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1:100-110.
37. Davis JN, Le KA, Walker RW, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010; 92:1522-1527.
38. Greenland S, Robins JM. Confounding and misclassification. Am J Epidemiol 1985; 122:495-506.